metastatic melanoma naive to immune therapy in metastatic setting
Showing 1 - 1 of 1
Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting Trial in Lausanne (Pembrolizumab, Pembrolizumab - additional
Active, not recruiting
- Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting
- Pembrolizumab
- Pembrolizumab - additional treatment
-
Lausanne, SwitzerlandOlivier Michielin
Jan 17, 2022